anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: Patients with cervical cancer who are diagnosed with venous thromboembolism (VTE) have worse outcomes compared to those not affected. There has yet to be a reliable method to predict or prevent VTE in cervical cancer patients. Our objective is to describe the incidence of VTE in patients with recurrent and metastatic (r/mCC) and determine risk factors that may predict VTE in this setting.
METHODS: We performed an observational cohort study of 386 patients with r/mCC who received at least one line of systemic chemotherapy. We collected demographic, clinical, histologic data and Khorana scores for all patients. Inclusion and exclusion criteria were applied before analysis. Statistical analysis was performed using Pearson chi-square, Student's t-test, and Wilcoxon rank-sum.
RESULTS: 232 patients were included for evaluation. Mean age was 49 years (range 20-83). The majority (167, 72%) of patients had squamous cell histology. 169 (72.8%) patients received treatment for recurrent disease and 63 (27.2%) for metastatic, stage IVB disease. 180 (78%) patients received prior radiation and 134 (58%) received bevacizumab. VTE was diagnosed in 89 (38%) patients. There were no statistically significant differences amongst clinical and pathologic characteristics between patients who developed VTE and those who did not. There was no significant association between BMI, Khorana score, radiation, bevacizumab, or immunotherapy and the development of VTE.
CONCLUSION: Approximately 40% of patients with r/mCC experienced a new VTE. There were no independent risk factors that could predict VTE in this population. Due to the overwhelmingly high incidence of VTE, prophylactic anticoagulation could be strongly considered in patients with r/mCC.
The invention discloses an oral medicine preparation for treating chronic cholecystitis. The oral medicine preparation is prepared from the following bulk drugs in parts by weight: 20-30 parts of angelica dahurica, 20-30 parts of cassia twigs, 5-15 parts of buthus martensi karsch scorpion, 5-15 parts of semen oroxyli, 10-20 parts of common selfheal fruit-spikes, 10-20 parts of climbing groundsel herbs, 5-15 parts of longtube ground ivy herbs, 20-30 parts of forsythia suspensa, 20-30 parts of coastal glehnia roots, 10-20 parts of lancea tibetica, 5-15 parts of roots of Indian kalimeris herbs, 10-15 parts of immature orange fruits, and 2-5 parts of musk. During treatment, the oral medicine preparation is taken orally twice a day, and 2-4 grams of the oral medicine preparation is taken each time. In one course of treatment, a patient takes the oral medicine preparation for 15 days continuously. For a patient with a slight state of the chronic cholecystitis, after the patient takes the oral medicine preparation for 2-3 courses of treatment, the chronic cholecystitis is healed; and for a patient with a serious state of the chronic cholecystitis, after the patient takes the oral medicine preparation for 3-5 courses of treatment, the chronic cholecystitis is healed. The oral medicine preparation for treating the chronic cholecystitis mainly treats the chronic cholecystitis, and through the application of the oral medicine preparation for many years, the effective rate reaches more than 95%. The oral medicine preparation has the advantages of stable therapeutic effect, significant effect, no toxic or side effects, low cost and the like.
African Americans have a greater prevalence than Caucasian Americans of hypertension, non-insulin-dependent diabetes mellitus, and cardiovascular disease. These conditions lead to substantial excess morbidity and mortality and are associated with and exacerbated by obesity, the prevalence of which is strikingly elevated in African American women. It is unknown if this increased prevalence of comorbid conditions is solely related to the greater prevalence of severe obesity among African American women, or due to differences in insulin sensitivity, glucose disposal, body composition, or fat cell metabolism. Through this project, we have verified that many of the physiological differences observed between African American and Caucasian adults are already present in obese children and in children at high risk for developing obesity. However, the roles that differences in energy expenditure, glucose metabolism, body composition, and other factors play in determining which children develop obesity and its comorbid conditions in adulthood remain unclear. In this study, we compare body composition, total and resting energy expenditure, and glucose disposal of obese African American and Caucasian children and of non-obese children of obese African American and Caucasian parents, to characterize the timing and nature of factors that may contribute to the prevalence of obesity and its complications. We also relate serum levels of the body-fat related circulating factors such as leptin, to these measures, and obtain samples for genomic DNA isolation from participants and their parents to characterize the roles of genes felt important for the development of obesity. We will follow these children for 15 years, studying them intensively at 5 year intervals until adulthood.
Highly active antiretroviral therapy (HAART) has greatly improved the life of HIV infected individuals. Before the introduction of HAART, the impact of HBV infection and liver disease was less prominent due to the rapid progression to AIDS. However, with the use of HAART, liver disease has become a leading cause of death in HIV infected individuals; therefore, prevention of HBV infection is essential. Most HIV infected people respond poorly to HBV vaccines. GM-CSF is a cytokine produced primarily by activated T and B cells and has been used extensively as a hematopoietic growth factor. GM-CSF increases neutrophil count, improves antigen-presenting cell function, and is involved in the development and improvement of cellular immune responses. Past research has shown that GM-CSF improves the immune response to HBV vaccination in people with kidney disease. The purpose of this study is to evaluate the safety and effectiveness of GM-CSF as an adjuvant to improve the immune response to HBV vaccination in HIV infected individuals.

This study will last 60 weeks. Participants will be randomly assigned to 1 of 2 arms. Arm A participants will receive 40 mcg of HBV vaccine at study entry, Week 4, and Week 12. Arm B participants will receive 40 mcg of HBV vaccine and 250 mcg of GM-CSF at study entry, Week 4, and Week 12. Participants will be stratified by their screening HIV-1 viral load. After completing the vaccination series, study visits will occur at Weeks 16, 36, and 60. Blood collection, a physical exam, and liver function and hepatitis antibody tests will be completed at all study visits. Telephone follow-up by study staff will occur 48 to 96 hours post-vaccination.
Participants will receive a fixed dose of RO7515629 intravenously as a single agent on cycle 0 day -7 and 7 days later on cycle 1 day 1 followed by every three-week dosing frequency. Treatment may continue for up to 12 months maximum or until progression, loss of clinical benefit, intolerable toxicity, withdrawal from study treatment or death.
Carcinogenicity studies have not been performed with ceritinib.

Ceritinib was not mutagenic in vitro in the bacterial reverse mutation (Ames) assay but induced numerical aberrations (aneugenic) in the in vitro cytogenetic assay using human lymphocytes, and micronuclei in the in vitro micronucleus test using TK6 cells. Ceritinib was not clastogenic in the in vivo rat micronucleus assay.

There are no data on the effect of ceritinib on human fertility. Fertility/early embryonic development studies were not conducted with ceritinib. There were no adverse effects on male or female reproductive organs in general toxicology studies conducted in monkeys and rats at exposures ≥ 0.5- and 1.5-fold, respectively, of the human exposure by AUC at the recommended dose.
FIELD: medicine, veterinary science, pharmacology. SUBSTANCE: immunotropic agent consists of Composite family plants extract at amount 0.5-75 wt.% and monoflower honey containing 3-hydroxyflavone-silibin at amount 25-99.5 wt.-%. An agent is obtained by processing the indicated composition by bees, being at least twofold, followed by fractionation by honey an aqueous solution freezing up to -60 C and the following defrosting to 15-30 C. Immunotropic agent stimulates immune processes, normalizes metabolism, shows an antibacterial, antiviral activity and inhibits growth of some tumor cell species. Invention can be used for prophylaxis and treatment of secondary immunodeficient states in viral, malignant and bacterial diseases. EFFECT: enhanced curative and prophylactic effectiveness of an agent. 5 cl, 1 tbl, 7 ex
Colorectal cancer (CRC) affects approximately 2 million people worldwide. Obesity is the major risk factor for CRC. In addition, obesity contributes to a chronic inflammatory stage that enhances tumor progression through the secretion of proinflammatory cytokines. In addition to an increased inflammatory response, obesity-associated cancer presents accrued molecular factors related to cancer characteristics, such as genome instability, sustained cell proliferation, telomere dysfunctions, angiogenesis, and microbial alteration, among others. Despite the evidence accumulated over the last few years, the treatments for obesity-associated CRC do not differ from the CRC treatments in normal-weight individuals. In this review, we summarize the current knowledge on obesity-associated cancer, including its epidemiology, risk factors, molecular factors, and current treatments. Finally, we enumerate possible new therapeutic targets that may improve the conditions of obese CRC patients. Obesity is key for the development of CRC, and treatments resulting in the reversal of obesity should be considered as a strategy for improving antineoplastic CRC therapies.
PURPOSE:To obtain a plaster from which the liner can be easily released, by dispersing the active component, etc., uniformly in a gel, applying the gel to a substrate, and forming protrusions free from the gel to the substrate. CONSTITUTION:A substrate 1 (e.g. woven rayon cloth, woven synthetic fiber cloth, etc.) having a definite shape is coated with a gel 2 containing uniformly dispersed active component, etc., and a liner is applied to the gel. The laminate is punched in a manner to leave the part 7 free from the gel as the protruded part 8. A plaster from which the liner can be easily released is produced by this process. The active component can be classified into a drug component (e.g. anti-inflammatory and analgesic agent, etc.) and a beautifying component (e.g. keratolytic agent, metabolism-promoting agent, etc.). The liner can be easily released from the plaster without trouble.
Treatment Plan GEMOX-Erlotinib consists of erlotinib 100 mg orally daily starting day 1, Gemcitabine 1000 mg/m2 in 10 mg/m2/min (100 minutes) infusion on day 1 followed on day 2 by oxaliplatin 100 mg/m2 in a 2-hour infusion. Treatment will be repeated every 2 weeks. Each two weeks is a cycle. Tumor response evaluation will be performed every 2 months. If tumor progress, patient will be off study, but if the disease is stable or PR, CR obtained will continue treatment for total of 12 cycles. If at end of 12 cycles response continues, will administer Gemox and erlotinib till achieve maximum response. Then start Erlotinib maintenance therapy.

Sample size: A total of 34 patients are needed assuming expected response is greater than 10% (about 27%) and a power = 80%. Fourteen patients will be treated in the first stage; if one patient achieved PR then additional twenty patients will be enrolled in the study for a total of 34 patients.

Statistical Methods: Response rate with 95% CI and median time to progression of disease will be calculated. Success will be declared if the lower limit of the 95% CI of the response rate is greater than 10%. The 95% CI of the response rate will be calculated using exact methods. Survival curve will be estimated using Kaplan-Meier Method. Descriptive statistics will be used to describe patient demographics, adverse events, serious adverse events and reasons for termination. Two approaches to the efficacy and safety analyses will be done; the ITT (intent-to-treat) for the efficacy analysis and safety. The ITT analysis consists of patients who received at least one dose of the study drug and at least one on-treatment measurement of the primary efficacy endpoint (overall response). The safety analysis consists of patients who received at least one dose of the study drug and at least one safety measurement done. A detailed description of the statistical methods, table and listing shells will be provided in the statistical analysis (SAP) before database lock or data transfer to the study biostatistician.
BACKGROUND: This study evaluated the cost-effectiveness of avelumab first-line (1L) maintenance therapy plus best supportive care (BSC) versus BSC alone for adults with locally advanced or metastatic urothelial carcinoma (la/mUC) that had not progressed following platinum-based chemotherapy in France.
METHODS: A three-state partitioned survival model was developed to assess the lifetime costs and effects of avelumab plus BSC versus BSC alone. Data from the phase 3 JAVELIN Bladder 100 trial (NCT02603432) were used to inform estimates of clinical and utility values considering a 10-year time horizon and a weekly cycle length. Cost data were estimated from a collective perspective and included treatment acquisition, administration, follow-up, adverse event-related hospitalization, transport, post-progression, and end-of-life costs. Health outcomes were measured in quality-adjusted life-years (QALYs) and life-years gained. Costs and clinical outcomes were discounted at 2.5% per annum. Incremental cost-effectiveness ratios (ICERs) were used to compare cost-effectiveness and willingness to pay in France. Uncertainty was assessed using a range of sensitivity analyses.
RESULTS: Avelumab plus BSC was associated with a gain of 2.49 QALYs and total discounted costs of €136,917; BSC alone was associated with 1.82 QALYs and €39,751. Although avelumab plus BSC was associated with increased acquisition costs compared with BSC alone, offsets of -€20,424 and -€351 were observed for post-progression and end-of-life costs, respectively. The base case analysis ICER was €145,626/QALY. Sensitivity analyses were consistent with the reference case and showed that efficacy parameters (overall survival, time to treatment discontinuation), post-progression time on immunotherapy, and post-progression costs had the largest impact on the ICER.
CONCLUSIONS: This analysis demonstrated that avelumab plus BSC is associated with a favorable cost-effectiveness profile for patients with la/mUC who are eligible for 1L maintenance therapy in France.
Asthma is a chronic, heterogeneous disease of the airways, often characterised by structural changes known collectively as airway remodelling. In response to environmental insults, including pathogens, allergens and pollutants, the epithelium can initiate remodelling via an inflammatory cascade involving a variety of mediators that have downstream effects on both structural and immune cells. These mediators include the epithelial cytokines thymic stromal lymphopoietin, interleukin (IL)-33 and IL-25, which facilitate airway remodelling through cross-talk between epithelial cells and fibroblasts, and between mast cells and airway smooth muscle cells, as well as through signalling with immune cells such as macrophages. The epithelium can also initiate airway remodelling independently of inflammation in response to the mechanical stress present during bronchoconstriction. Furthermore, genetic and epigenetic alterations to epithelial components are believed to influence remodelling. Here, we review recent advances in our understanding of the roles of the epithelium and epithelial cytokines in driving airway remodelling, facilitated by developments in genetic sequencing and imaging techniques. We also explore how new and existing therapeutics that target the epithelium and epithelial cytokines could modify airway remodelling.
This is a pilot randomized controlled study that aims to develop CircaHealth: an online course on practices, known as circadian hygiene, that promote circadian rhythm alignment and minimize circadian rhythm misalignment. The project also will determine the feasibility, acceptability, and preliminary effects of CircaHealth in improving circadian rhythm related measures in University of Miami Miller School of Medicine medical students.

The educational videos will be incorporated into a six-module online course which contains additional educational and behavior modification tools. Medical students (n = 40) will be recruited via email and randomized to receive CircaHealth or materials from the National Sleep Foundation and/or the American Academy of Sleep Medicine. Sleep, mood, and circadian hygiene knowledge, behaviors, and attitudes will be assessed at baseline and four weeks post intervention. Feasibility will be determined by CircaHealth module completion rates, and acceptability will be assessed via a self-report survey. Changes in sleep quality measures between groups will determine the preliminary efficacy of CircaHealth.
Epidemiologic data are few but suggest that effects during the prenatal and early life periods may be important in influencing risk of breast, prostate and testicular cancers later in life. In particular, evidence is accumulating for associations with several maternal, perinatal and pregnancy characteristics, including twining. The effect of these factors may be mediated through alterations in hormone levels such as the estrogens and other steroid hormones, to which the embryo and fetus are exposed during pregnancy. Differences in maternal hormone concentrations by maternal and perinatal factors have been noted, though data for most factors are sparse. Furthermore, less is known about the relationships of pregnancy factors to hormones in cord blood, the proximal exposure to the fetus, since most work thus far has been based on hormones in the maternal circulation. In collaboration with investigators at Dartmouth Hitchcock Medical Center, we are collecting maternal and cord blood samples from monochorionic twin, dichorionic twin and singleton pregnancies of similar gestational age to quantify differences in concentrations of several hormones and other pregnancy products. The purpose of the study is to assess the consistency of these data with hypotheses regarding the altered cancer risk daughters of twin pregnancies experience. All data collection is completed. We are currently analyzing the data for development of manuscripts to be submitted for publication.
The present invention provides antiphlogistic medicine characterized in that the antiphlogistic medicine is prepared from the following raw materials of one to six portions of spatholobus stem, three to ten portions of caesalpinia, two to eight portions of plant soot, and one to three portions of borneol. The antiphlogistic medicine has the effects for clearing away heat and toxic materials, strengthening throats, relieving inflammation, relaxing pain, dispelling wind, eliminating dampness, activating blood, dissolving stasis, resolving turbidity, removing dampness, relieving itch, astringing, promoting tissue regeneration, etc. The antiphlogistic medicine has peculiar effects on detoxification, inflammation relieving, analgesia, hemostasis, itch relieving, etc. The antiphlogistic medicine does not have poison or side effects. When the antiphlogistic medicine is orally taken, the antiphlogistic medicine can treat the inflammation on upper respiratory tracts, such as stomatitis, pharyngitis, tonsillitis, tracheitis, etc., the gastroenteritis, such as cholecystitis, gastritis, enteritis, etc., and the inflammation, such as cystitis, urethritis, pelvic inflammation, hemorrhoid, etc. When the antiphlogistic medicine is externally used, the antiphlogistic medicine can treat cutaneous pruritus, tinea of feet and hands, dermatoneuritis, herpes zosters, eczema, burn, traumatic bleeding, wound infection, etc. The antiphlogistic medicine has the advantages of favorable curative effect and wide popularization.
The invention relates to a selenium germanium peptide biscuit belonging to the health products field, which is characterized in that: the biological trace element selenium, germanium and peptide are added into the biscuit, and the modifying agent adopts jujube, wheat germ and medlar extract, which is taken as water and flour, and is dried in 80 deg C in the cooking process, namely pasteurization method. The biscuit is suitable for the children, the elderly and the sick personnel. The invention has the functions of trace elements supplement, bacteria resistance and inflammation elimination, improvement of immunocyte, the enhancement of immunity and disease resistance, as well as health protection. The jujube, wheat germ and medlar are added as the fruit sugar without preservative and antistaling agent so as to prevent the obesity of children and avoid the children to be precocious. The jujube can improve vital energy; the sealwort and medlar can make the skin tender and the body light. Thereby, the hair is black and bright. The biscuit is a healthy food (with green standard); as the product passes the ISO9001 certification, the invention will be an organic food.
A cosmetic composition in the form of an aerosol spray for hair control contains a solvent; a film-forming tetrapolymer resulting from the copolymerization of (a) 5 to 10 wt. % acrylic acid, (b) 20 to 52 wt. % N,N-dimethylacrylamide, (c) 3 to 28 wt. % of N-tert-butylacrylamide, and (d) 20 to 45 wt. % ethyl methacrylate, the carboxylic acid functions of the tetrapolymer being at least partially neutralized with a mineral or organic base; and at least one non-halogen propellant gas. This spray provides excellent hair control, and the film-forming substance does not cause stickiness of the hair over time and is easily eliminated by washing with a shampoo.
The invention discloses a traditional Chinese medicine composition for curing hepatitis B as well as a preparing method and application of the traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from the following ingredients in parts by weight: 8-13 parts of picrasma quassioides root, 6-12 parts of herba potentillae discoloris, 7-13 parts of euryales semen, 5-7 parts of cortex eucommiae, 3.5-5.2 parts of alpiniae katsumadai semen and 3.5-4.8 parts of pedicellus melo. The picrasma quassioides root and the pedicellus melo are washed, mixed and soaked into an ethanol solution for soaking, the picrasma quassioides root and the pedicellus melo are extracted in a microwave-assisted manner and filtered to obtain filtrate and filter residue, and the filtrate is concentrated into thick paste. The herba potentillae discoloris, the euryales semen, the cortex eucommiae and the alpiniae katsumadai semen are washed and evenly mixed with the filter residue; then the herba potentillae discoloris, the euryales semen, the cortex eucommiae and the alpiniae katsumadai semen are soaked in water, decocted, extracted and filtered; and finally the herba potentillae discoloris, the euryales semen, the cortex eucommiae and the alpiniae katsumadai semen are concentrated into extractum in a decompressing manner. The thick paste and the extractum are mixed to be manufactured into granules. Thus, the traditional Chinese medicine composition can be obtained. The traditional Chinese medicine composition has the effects of clearing heat and toxic materials, inducing dieresis to reduce edema, regulating qi to alleviate pain, calming the liver and facilitating the gallbladder and has an obvious curing effect on hepatitis B. In addition, clinical verifications show that the effective rate can reach 94-98%.